Inicio
Volver a la pantalla de resultados de la última búsqueda | Consultar el historial de búsquedas | Volver a la pantalla de inicio |
Resultado de la búsqueda
2 búsqueda de la palabra clave 'Positron emission tomography'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial / Sergio Álvarez Vallejo
Título : A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial Tipo de documento : documento electrónico Autores : Sergio Álvarez Vallejo, Fecha de publicación : 2022 Títulos uniformes : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : Alzheimer’s disease amyloid antibody data sharing magnetic resonance imaging positron emission tomography presenilin 1 primary prevention secondary prevention Resumen : Introduction: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data. Methods: We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data. Results: Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers. Discussion: Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition. Mención de responsabilidad : Eric M. Reiman, Jeremy J. Pruzin, Silvia Rios-Romenets, Chris Brown, Margarita Giraldo, Natalia Acosta-Baena, Carlos Tobon, Nan Hu, Yinghua Chen, Valentina Ghisays, Jessica Enos, Dhruman D. Goradia, Wendy Lee, Ji Luo, Michael Malek-Ahmadi, Hillary Protas, Ronald G. Thomas, Kewei Chen, Yi Su, Connie Boker, Diego Mastroeni, Sergio Alvarez, Yakeel T. Quiroz, Jessica B. Langbaum, Kaycee M. Sink, Francisco Lopera, Pierre N. Tariot, and the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov 14. DOI (Digital Object Identifier) : 10.1002/alz.12843 PMID : 36373344 Derechos de uso : CC BY-NC En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12843 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6100 A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial [documento electrónico] / Sergio Álvarez Vallejo, . - 2022.
Obra : Alzheimer's & Dementia
Idioma : Inglés (eng)
Palabras clave : Alzheimer’s disease amyloid antibody data sharing magnetic resonance imaging positron emission tomography presenilin 1 primary prevention secondary prevention Resumen : Introduction: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data. Methods: We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data. Results: Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers. Discussion: Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition. Mención de responsabilidad : Eric M. Reiman, Jeremy J. Pruzin, Silvia Rios-Romenets, Chris Brown, Margarita Giraldo, Natalia Acosta-Baena, Carlos Tobon, Nan Hu, Yinghua Chen, Valentina Ghisays, Jessica Enos, Dhruman D. Goradia, Wendy Lee, Ji Luo, Michael Malek-Ahmadi, Hillary Protas, Ronald G. Thomas, Kewei Chen, Yi Su, Connie Boker, Diego Mastroeni, Sergio Alvarez, Yakeel T. Quiroz, Jessica B. Langbaum, Kaycee M. Sink, Francisco Lopera, Pierre N. Tariot, and the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov 14. DOI (Digital Object Identifier) : 10.1002/alz.12843 PMID : 36373344 Derechos de uso : CC BY-NC En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12843 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6100 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001948 AC-2022-109 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-109Adobe Acrobat PDF Scar sarcoidosis: A rare entity found by 18F-FDG-PET/CT / Mónica Alexandra Vidal González ; Juan Esteban López Amaya ; Jhonny Alberto Sierra Marín ; Ana Cristina Ruiz Suárez
Título : Scar sarcoidosis: A rare entity found by 18F-FDG-PET/CT Tipo de documento : documento electrónico Autores : Mónica Alexandra Vidal González, ; Juan Esteban López Amaya, ; Jhonny Alberto Sierra Marín, ; Ana Cristina Ruiz Suárez, Fecha de publicación : 2018 Títulos uniformes : Radiology Case Reports Idioma : Inglés (eng) Palabras clave : Scar sarcoidosis Positron emission tomography FDG Resumen : F-labeled fluoro-2-positron deoxyglucose emission tomography/computed tomography has been widely used in malignancy assessment, however, is not tumor-specific and may be taken up by non-malignant conditions such as sarcoidosis. Sarcoidosis is a systemic inflammatory disorder and scar sarcoidosis is a rare manifestation of the disease. A 60-year-old man with a past medical history of synchronous colon adenocarcinoma and clear cell renal cell carcinoma with clinical suspicion of tumor recurrence. 18 F-labeled fluoro-2-positron deoxyglucose emission tomography/computed tomography scan demonstrated lesions with increased fluorodeoxyglucose uptake in mediastinal and left supraclavicular lymph nodes, along with hypermetabolic cutaneous foci that corresponded with previous surgical scars. Skin biopsy was suggestive of sarcoidosis. Mención de responsabilidad : M Vidal, A Alvarado, J López, J Sierra, A Ruíz Referencia : Radiol Case Rep. 2018 Sep 15;13(6):1216-1219. DOI (Digital Object Identifier) : 10.1016/j.radcr.2018.07.023 PMID : 30233763 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1930-0433(18)30204-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4154 Scar sarcoidosis: A rare entity found by 18F-FDG-PET/CT [documento electrónico] / Mónica Alexandra Vidal González, ; Juan Esteban López Amaya, ; Jhonny Alberto Sierra Marín, ; Ana Cristina Ruiz Suárez, . - 2018.
Obra : Radiology Case Reports
Idioma : Inglés (eng)
Palabras clave : Scar sarcoidosis Positron emission tomography FDG Resumen : F-labeled fluoro-2-positron deoxyglucose emission tomography/computed tomography has been widely used in malignancy assessment, however, is not tumor-specific and may be taken up by non-malignant conditions such as sarcoidosis. Sarcoidosis is a systemic inflammatory disorder and scar sarcoidosis is a rare manifestation of the disease. A 60-year-old man with a past medical history of synchronous colon adenocarcinoma and clear cell renal cell carcinoma with clinical suspicion of tumor recurrence. 18 F-labeled fluoro-2-positron deoxyglucose emission tomography/computed tomography scan demonstrated lesions with increased fluorodeoxyglucose uptake in mediastinal and left supraclavicular lymph nodes, along with hypermetabolic cutaneous foci that corresponded with previous surgical scars. Skin biopsy was suggestive of sarcoidosis. Mención de responsabilidad : M Vidal, A Alvarado, J López, J Sierra, A Ruíz Referencia : Radiol Case Rep. 2018 Sep 15;13(6):1216-1219. DOI (Digital Object Identifier) : 10.1016/j.radcr.2018.07.023 PMID : 30233763 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1930-0433(18)30204-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4154 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000768 AC-2018-055 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2018-055.pdfAdobe Acrobat PDF